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Abstract
The age- and cytomegalovirus (CMV)-seropositivity-related changes in subsets and differentiation of circulating
T cells were investigated in end-stage renal disease (ESRD) patients (n = 139) and age-matched healthy individuals.
The results show that CMV-seropositivity is associated with expansion of both CD4
+ and CD8
+ memory T cells
which is already observed in young healthy individuals. In addition, CMV-seropositive healthy individuals have a
more differentiated memory T cell profile. Only CMV-seropositive healthy individuals showed an age-dependent
decrease in CD4
+ naïve T cells. The age-related decrease in the number of CD8
+ naïve T cells was
CMV-independent. In contrast, all ESRD patients showed a profound naïve T-cell lymphopenia at every decade.
CMV-seropositivity aggravated the contraction of CD4
+ naïve T cells and increased the number of differentiated
CD4
+ and CD8
+ memory T cells. In conclusion, CMV-seropositivity markedly alters the homeostasis of circulating
T cells in healthy individuals and aggravates the T cell dysregulation observed in ESRD patients.
Introduction
End-stage renal disease (ESRD) is associated with an
immune defect characterized by increased susceptibility
for infections and decreased humoral responses to
T-cell dependent antigens like HBsAg [1,2]. Circulating
T lymphocytes can be dissected into subsets of naïve
and memory T lymphocytes using the common leuko-
cyte antigen CD45RO (memory marker) and the chemo-
kine receptor CCR7 which is important for homing of T
cells to lymphoid organs. Differential expression of
CD45RO and CCR7 allows for further dissection of
functionally different T lymphocyte subsets; naïve T
cells (Tnaive, expressing CCR7), central-memory T cells
(Tcm, expressing CCR7) and effector-memory (Tem, no
expression of CCR7) [3]. In addition, within the CD8
+
T lymphocyte subset an extra late effector memory
population can be distinguished, lacking both CCR7 and
CD45RO (Temra) [4,5]. The loss of expression of the
co-stimulatory molecule CD28 and increased expression
of CD57 on memory T cells is indicative of a later stage
of differentiation of T cells with diminished replicative
capacity [6].
Progressive loss of renal function is associated with a
progressive decrease in the size of the the naïve T cell
compartment, a decrease within CD4
+ Tcm lymphocytes
and a significant increase in CD8
+ Temra [7,8]. In addi-
t i o n ,w eh a v ed e m o n s t r a t e dt hat the severely impaired
humoral response of ESRD patients to HBV vaccination
can be attributed to a specific deficit in the generation
of antigen-specific effector-memory CD4
+ Tc e l l s[ 9 ] .
Therefore, the disturbed composition of circulating
T cells in ESRD patients seems to underly, at least
partly, their immune deficiency.
Cytomegalovirus (CMV) seropositivity is known to
have a major impact on the repertoire of antigen speci-
fic T cells as an estimated 10% of circulating T cells is
CMV-antigen specific in seropositive individuals [10]. In
addition, the changes generally observed with an aged
immune system, like a decreased CD4/CD8 ratio and
expansion of CD28 negative CD8
+ positive T cells seem
to be related to CMV seropositivity [11-13]. The preva-
lence of CMV seropositivity increases with age and varies
with socio-economic and ethnic background from 30 to
100% [14]. Therefore, any analysis of age-related changes
of the immune system should take CMV-seropositivity
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interaction between CMV-seropositivity and ageing on
the absolute numbers of circulating T cell subsets in
healthy controls [11,15,16]. Although these studies indi-
cated an CMV-related increase in total numbers of CD8
+
T cells, they reached dissimilar conclusions with respect
to CMV-related changes of T cells at young age which
may be due to differences in definition of the various
T cell populations.
ESRD patients have increased numbers of circulating
CD8
+ Temra cells and CD28 negative T cells suggesting
am a j o ri n f l u e n c eo fC M Vs e r o p o s i t i v i t yo nTc e l l
immunity [17]. However, it is not known how CMV and
ageing interact and contribute to the observed ESRD-
related changes in numbers of circulating T cells
subsets. A carefull dissection of the influence of these
different factors (loss of renal function, age and CMV
seropositivity) on circulating T cells is pivotal to under-
stand the ESRD-related immune deficiency.
To examine this question, we have performed a large
cross-sectional study including ESRD patients and
healthy donors.
Material and methods
Subjects
Patients aged 18 to 78 years were recruited for the study
from our outpatient clinic for renal transplantation dur-
ing a period of 2.5 years. All patients had ESRD, defined
as an estimated glomerular filtration rate of less then 15
mL/min with or without renal replacement therapy.
Patients with a malignancy, active infection or taking
immunosuppressive drugs were excluded. The healthy
individuals were recruited from their relatives, thereby
matching for socio-economic and ethnical background.
All patients and healthy controls included gave informed
consent and the local medical ethical committee
approved the study. It was conducted according to the
principles of Declaration of Helsinki and in compliance
with International Conference on Harmonization/Good
Clinical Practice regulations. Study population charac-
teristics are depicted in Table 1. We aimed at 5 to 10
CMV-seropositive and -seronegative individuals at each
age-decade.
Flowcytometric analysis of the various T lymphocyte
subsets
To determine the percentages and absolute numbers of
the various T lymphocytes, we performed a whole blood
staining as described previously but with some minor
adjustments [7]. Briefly, to distinguish the various T
lymphocyte subsets, we used AmCyan-labelled CD3
(BD, Erembodegem, Belgium) with either peridinin
chlorophyll protein (PerCP)-labelled CD4 or CD8 in
combination with allophycocyanin (APC)-labelled
CD45RO (BD) or Pacific Blue-labelled CD45RO (Biole-
gend Europe B.V, Uithoorn, Netherlands), and fluores-
cein isothiocyanate (FITC)-labelled CCR7 (R&D Systems
Europe Ltd, Abingdon, UK). The various subsets are
defined as CD4
+ or CD8
+ and either naive being CCR7
+
CD45RO
- (Tnaive) or belonging to the memory popula-
tion (Tmem). The latter can be further dissected in cen-
tral memory being CCR7
+ CD45RO
+ (Tcm), effector
memory being CCR7
-CD45RO
+ (Tem) and for the CD8
+ T lymphocytes, Temra being CCR7
- CD45RO
-.I n
addition, percentages of CD28
- (CD28null) and CD57
+
for CD4
+ and CD8
+ T lymphocytes were determined
using phycoerythrin (PE)-labelled CD28 (BD) and APC-
labelled CD57 (Biolegend), respectively. For each mea-
surement, we acquired 50000 lymphocytes to ensure
reliable results. Analysis was performed using the FACS
Canto™ II (BD) and FACSDIVA software (BD).
CMV serology
Serum IgG antibodies to CMV were measured with an
enzyme immuno assay (Biomerieux, VIDAS, Lyon,
France) and expressed as arbitrary units/ml (AU/mL).
Following the manufacturers guidelines, a test result
exceeding 6 AU/mL was considered positive for the pre-
sence of CMV-specific IgG antibodies.
Statistical analysis
The non-parametric Spearman’s rank correlation (Rs)
test was performed to analyze correlations between age
and the various T lymphocytes subsets in the group of
healthy individuals and ESRD patients. ESRD patients
and their age-matched healthy controls were divided
into two groups; 20-40 years (young) and 60-80 years
(old), to evaluate the effect of CMV seropositivity on the
composition of the T lymphocyte compartment. The
Mann-Whitney U-test wasu s e dt oc o m p a r ev a l u e s
between CMV-seronegative and seropositive individuals
as well as to compare ESRD patients to healthy donors.
Distribution of gender and CMV-seropositivity was
tested using the Chi-square test. P-values less than 0.05
were considered significant. The SPSS software version
17 was used for all statistical tests.
Results
CMV-seropositivity is associated with increased T cell
numbers and differentiation to a memory-effector
phenotype in healthy young individuals
At young age, the absolute number of CD4
+ and CD8
+ T
cells was increased in CMV-seropositive healthy indivi-
duals by 76% and 83%, respectively when compared to
CMV-seronegative healthy individuals (Table 2). Both
the naïve and memory T cells showed increased cell
numbers, although the memory compartment contribu-
ted for the largest part (48% for CD4
+ and 64% for CD8
+
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+ and CD8
+ T memory cells
a significant increase in differentiation towards the effec-
tor-memory phenotype was observed. Within the memory
compartment, the CD4 Tem increased by 2.1-fold and the
CD8 Tem by 1.5-fold. The memory CD8
+ T cells showed
the highest degree of differentiation to an effector pheno-
type as the Temra cells were on average 2.3-fold increased
in CMV-seropositive healthy donors (Table 2).
CMV-seropositivity selectively influences T cell subsets
with increasing age
With increasing age, the CD4
+ T lymphocyte population
and the different subsets remained remarkably unaffected
in CMV-seronegative persons over a period of 4 to 5 dec-
ades (Figure 1B and Figure 2A-D, straight line). However,
in CMV-seropositive healthy individuals the elevated
CD4 T cell numbers at young age, specifically the Tnaive,
decreased to values similar to seronegative persons at old
age (Table 2 Figure 1B and Figure 2A, dotted line).
T h ef i n d i n g sw e r ev e r yd i f f e r e n tf o ra g e - r e l a t e d
changes of CD8
+ T cells. Most notably, a steep decrease
(> 80%) was observed in Tnaive cell numbers which was
unaffected by CMV- seropositivity. In CMV-seronega-
tive individuals this resulted in a modest decrease of the
total CD8
+ T cell population, as the Tmem remained
unchanged with increasing age (Table 2). In CMV-
seropositive individuals the CD8
+ Tmem increased sig-
nificantly (P = 0.02) with increasing age (Figure 3E), an
effect which could be observed in all memory subpopu-
lations although statistical significance was not reached
(Figure 3B-D). This resulted in a significantly age-related
decrease in the CD4/CD8 ratio (P < 0.01) in CMV-sero-
positive healthy individuals, but not in CMV seronega-
tive individuals (data not shown).
Impact of CMV-seropositivity on composition of
T lymphocytes subsets in ESRD patients
Compared to CMV-seropositive healthy individuals,
ESRD patients have a significantly (P < 0.01) lower num-
ber of T lymphocytes which is related to a relative CD4
+
T cell lymphopenia at all ages. The decreased CD4
+ T
cell numbers are caused by a significant decrease in Tna-
ive and Tcm as has been described before [7]. The CD4
+
Tnaive decreased with increasing age but this association
was only statistically significant (P < 0.01) in CMV-
seropositive patients (Figure 2E), and resulted in a signifi-
cantly (P = 0.03) lower number of Tnaive at old age in
CMV-seropositive patients (Table 3).
Table 1 Study population characteristics
ESRD patients healthy controls P-value
number of individuals 139 111
age (yrs)* 46 (18-78) 50 (21-78) 0.13
sexe (male) 75% 48% < 0.01
CMV seropositive 53% 59% 0.10
CMV IgG (AU/mL)* 54 (6-252) 47 (6-199) 0.54
underlying kidney disease
hypertensive nephropathy 36.6%
primary glomerulopathy 20.1%
diabetic nephropathy 7.5%
polycystic kidney disease 0.0%
other 30.6%
unknown 5.2%
type of renal replacement therapy
hemodialysis 41%
peritoneal dialysis 24.6%
previous kidney transplantation 4.5%
none 29.9%
* values are median (range), percentages are means.
Distribution of gender and CMV-seropositivity within the healthy donor and ESRD patients was tested using the Chi-square test. Gender did not significantly alter
the composition of T lymphocyte subsets.
Comparison between the healthy donors and ESRD patients with respect to age, CMV-serology was tested using the Mann-Whitney U-test.
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+ T
memory compartment (Figure 1E) and its subsets (Figure
2E-H) remained stable with age, irrespective of CMV-ser-
ostatus. The influence of CMV-seropositivity on differen-
tiation to an effector memory phenotype was less clear in
ESRD patients, compared to healthy individuals.
The CD8
+ Tnaive population showed a very signifi-
cant age-related decrease, irrespective of CMV-serosta-
tus and with a similar slope as healthy individuals. At all
ages, CD8
+ T lymphocytes of CMV-seropositive ESRD
patients are significantly higher due to an increased
Tmem when compared to their seronegative counter-
parts similar to healthy donors. The Tmem does not
increase with age (Figure 3J) as was observed for CMV-
seropositive healthy individuals. At young age, CD8
+
Temra and Tmem are approximately 6- and 1.6-fold
increased whereas at old age the values are 5.5- and 1.7-
fold (Table 3). The decrease of Tnaive cell numbers but
unchanged Tmem subsets led to a significant age-related
decrease of total CD8
+ T cell numbers in ESRD patients
(Figure 1F).
CMV seropositivity and ESRD increase CD57 expression
and loss of CD28 on memory T cells
Markers specific for terminal differentiation of T lym-
phocytes, i.e. loss of CD28 expression (CD28null) and
percentages CD57
+ T lymphocytes are specifically higher
within CD4
+ Tmem of CMV-seropositive healthy indivi-
duals. Similar results were obtained for percentages of
CD28null, but not CD57
+, Tmem cells within the CD8
+
T lymphocyte compartment. With increasing age, these
markers remained stable (Table 2).
Similar to the healthy counterparts, significantly
higher percentages of CD28null and CD57
+ in both
CD4
+ and CD8
+ Tmem lymphocytes were observed in
CMV-seropositive ESRD patients (Table 3). Moreover in
contrast to healthy donors, a significant increase in per-
centages of CD28null CD4
+ Tmem was observed when
old ESRD patients were compared to young ones (Table
3, 11.9% to 4.0%, p < 0.001). Also, the percentage of
CD57 positive CD4
+ Tmem was significantly higher in
CMV-seropositive ESRD patients as compared to
healthy controls (at young age 34.0% versus 18.1% and
at old age 35.7% versus 13.2% for CMV-seropositive
ESRD patients and CMV-seropositive healthy donors,
respectively, p < 0.01.)
Discussion
In this study we have analyzed the differential and com-
bined effects of age, CMV latency and loss of renal
function on numbers and composition of the various
T lymphocytes. The results show that CMV latency,
Table 2 The effect of age and cytomegalovirus (CMV) serostatus on the various T lymphocytes for healthy donors
young (20-40 yrs) elderly (> 60 yrs)
CMV- (N = 15) CMV+ (N = 17) CMV- (N = 21) CMV+ (N = 23)
mean ± SEM mean ± SEM P-value mean ± SEM mean ± SEM P-value
T lymphocytes 0.77 ± 0.07 1.39 ± 0.13 <0.01 0.91 ± 0.1 1.03 ± 0.09 0.19
CD4
+ T lymphocytes 0.49 ± 0.06 0.86 ± 0.09 <0.01 0.63 ± 0.08 0.63 ± 0.06 0.74
Tnaive 0.17 ± 0.02 0.36 ± 0.05 0.01 0.25 ± 0.05 0.21 ± 0.03 0.61
Tcm 0.2 ± 0.03 0.26 ± 0.02 0.08 0.21 ± 0.02 0.23 ± 0.03 0.91
Tem 0.07 ± 0.01 0.15 ± 0.02 <0.01 0.08 ± 0.01 0.11 ± 0.01 0.05
Tmem 0.27 ± 0.04 0.4 ± 0.04 0.02 0.29 ± 0.03 0.34 ± 0.04 0.38
*CD28null 0.11 ± 0.02 4.21 ± 0.98 <0.01 0.34 ± 0.17 4.73 ± 1.36 <0.01
*CD57
+ 5.23 ± 0.71 18.11 ± 3.88 0.04 6.46 ± 0.69 13.18 ± 3.77 0.34
CD8
+ T lymphocytes 0.23 ± 0.02 0.42 ± 0.04 <0.01 0.22 ± 0.03 0.34 ± 0.03 <0.01
Tnaive 0.15 ± 0.03 0.22 ± 0.04 0.28 0.06 ± 0.01 0.06 ± 0.01 0.54
Tcm 0.04 ± 0.01 0.04 ± 0.01 0.77 0.05 ± 0.01 0.08 ± 0.02 0.55
Tem 0.06 ± 0.01 0.09 ± 0.02 0.08 0.07 ± 0.01 0.11 ± 0.02 0.05
Temra 0.04 ± 0.01 0.09 ± 0.02 0.01 0.06 ± 0.02 0.11 ± 0.02 0.01
Tmem 0.14 ± 0.01 0.23 ± 0.03 0.01 0.18 ± 0.03 0.3 ± 0.03 <0.01
*CD28null 31.89 ± 5.12 47.82 ± 4.13 0.04 27.78 ± 3.52 43.28 ± 4.47 0.02
*CD57
+ 38.39 ± 8.67 49.63 ± 6.14 0.34 29.21 ± 2.79 49.65 ± 9.38 0.03
CD4/CD8 ratio 2.06 ± 0.35 2.13 ± 0.18 0.571 3.58 ± 0.38 2.05 ± 0.20 <0.01
absolute values are 10
6/mL, Tmem is sum of Tcm+Tem or sum of Tcm+Tem+Temra for CD4 and CD8 T lymphocytes, respectively.
* are percentages of CD4+ and CD8+ Tmem lymphocytes, respectively.
P-values represent the comparison between CMV- and CMV+.
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circulating T cell numbers, composition and age-related
effects of the immune system. Moreover, CMV aggra-
vates some pre-existing changes in the T cell compart-
ment of ESRD patients.
A remarkably stable composition of the CD4
+ T cell
compartment was noted in CMV-seronegative healthy
donors over an age span of at least 5 decades. Both total
number of CD4
+ T cells and relative distribution
remained unchanged in the elderly population. In con-
trast, the CD8
+ naive T cell subset showed a major
age-related decline while the memory compartment
remained stable with respect to differentiation and
expressing of ageing markers CD28null and CD57. The
preferential age-related decrease of CD8 Tnaive cells is
in accordance with previous studies [18] and, although
speculative, may be caused by a higher antigen driven
turnover of these cells as compared to CD4
+ Tn a i v e
cells.
CMV-seropositivity has a large effect on CD4
+ and
CD8
+ T cell subsets at all ages in healthy individuals. It
is associated with increased numbers of all CD4
+ T cells
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Figure 1 Age-related effects of CMV on composition of T lymphocytes. The lines of the best fits are shown for absolute numbers of T
lymphocytes (A, D), CD4
+ (B, E) and CD8
+ T lymphocytes (C, F) of healthy volunteers (A, B, C) and ESRD patients (D, E, F) against age on X-axis
and CMV serostatus (dotted line = CMV seropositive and closed line = CMV seronegative).
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Figure 2 Age-related effects of CMV on CD4
+ T cell subsets. The lines of the best fits are shown for absolute numbers of CD4
+ Tnaive (A, E),
Tcm (B, F), Tem (C, G) and Tmem (D, H) of healthy volunteers (A, B, C, D) and ESRD patients (E, F, G, H) against age on X-axis and CMV serostatus
(dotted line = CMV seropositive and closed line = CMV seronegative).
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Figure 3 Age-related effects of CMV on CD8
+ T cell subsets. The lines of the best fits are shown for absolute numbers of CD8
+ Tnaive (A, F),
Tcm (B, G), Tem (C, H), Temra (D, I) and Tmem (E, J) of healthy volunteers (A, B, C, D, E) and ESRD patients (F, G, H, I, J) against age on X-axis and
CMV serostatus (dotted line = CMV seropositive and closed line = CMV seronegative).
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Page 7 of 10at young age and smaller numbers at old age, in particu-
lar within the Tnaive cell subset.
CMV-seropositivity was associated with a different
effect on CD8
+ T cells, as only the memory T cell com-
partement was significantly and stably expanded. The
slope of the age-related decline of CD8 Tnaive was not
affected by CMV-seropositivity. Confirming previous
results, the appearance of CD28null cells within the
CD4
+ Tmem cell compartment seemed pathognomonic
for CMV-seropositivity, but was unaffected by increasing
age [15,17,19]. Overall, the results indicated that loss of
CD28 expression and increased expression of CD57 on
CD4
+ and CD8
+ T cells was highly associated with
CMV-seropositivity. These markers should therefore be
interpretated with care in clinical studies that study the
ageing of T cells, taking into account the potential con-
founder of increasing prevalence of CMV-seropositivity
with age. Hypothetical extrapolation of the regression
lines of the total CD4
+ and CD8
+ T cell (sub) popula-
tions beyond 80 years results in a lowered CD4/CD8 T
cell ratio, lowered Tnaive cell numbers and an increased
percentage of memory T cells with a higher percentage
of CD28null cells. These findings have indeed been
described in the healthy very old and specifically in rela-
tion with CMV-seropositivity [11,20,21]. Therefore, it
seems likely that the changes seen in the age span from
20 to 80 years continue within the ninth and tenth
decade. The CMV-seropositivity related changes of the
T cell immune system at old age are associated with an
increased risk for mortality and therefore seem to be of
clinical significance. Destabilization of atherosclerotic
plaques by CD4
+CD28null T cells [17] or immune sup-
pressor activity of CD8
+CD28null T cells [22,23] may
explain this increased risk for mortality in elderly CMV-
seropositive individuals.
The age-related decrease in the number of CD4
+ and
CD8
+ Tnaive cells with CMV-seropositivity explains the
reported age-related increased of memory T cells when
percentages and not absolute numbers of cells are used
[24]. However, studies involving human subjects that
have reported absolute numbers of circulating T cell
subsets in relation to age and CMV seropositivity are
scarce [15,16]. As our results clearly show, latency for
C M Vi sa s s o c i a t e dw i t has t a b l ei n c r e a s eo fm e m o r y
CD8
+ T cells and an increase of memory CD4
+ T cells
at young age. This is in sharp contrast to the results
from the study by Chidrawar [16], which may be
explained by the relative low number of young CMV-
seropositive individuals in this study, but similar to data
obtained by Looney et al. [15].
It is known that CMV antigen-specific T cells may be
present at a high frequency within the pool of circulat-
ing CD4
+ and CD8
+ Tc e l l s[ 2 5 , 2 6 ] ,b u to u rr e s u l t sa r e
not in support of a limited immunological space [24,27]
Table 3 The effect of age and cytomegalovirus (CMV) serostatus on the various T lymphocytes for ESRD patients
young (20-40 yrs) elderly (> 60 yrs)
CMV- (N = 27) CMV+ (N = 23) CMV- (N = 15) CMV+ (N = 25)
mean ± SEM mean ± SEM P-value mean ± SEM mean ± SEM P-value
T lymphocytes 0.72 ± 0.08 0.86 ± 0.1 0.47 0.48 ± 0.04 0.6 ± 0.04 0.09
CD4
+ T lymphocytes 0.46 ± 0.05 0.46 ± 0.06 0.90 0.35 ± 0.03 0.36 ± 0.03 0.87
Tnaive 0.2 ± 0.03 0.17 ± 0.04 0.73 0.13 ± 0.02 0.08 ± 0.01 0.03
Tcm 0.15 ± 0.02 0.14 ± 0.02 0.61 0.13 ± 0.02 0.13 ± 0.02 0.85
Tem 0.07 ± 0.01 0.09 ± 0.02 0.52 0.06 ± 0.01 0.09 ± 0.01 0.01
Tmem 0.21 ± 0.02 0.23 ± 0.03 0.93 0.18 ± 0.03 0.22 ± 0.02 0.28
*CD28null 0.05 ± 0.01 4.05 ± 0.83 <0.01 0.82 ± 0.69 11.91 ± 2.79 <0.01
*CD57
+ 9.93 ± 1.24 34.02 ± 7.09 <0.01 7.61 ± 1.77 35.71 ± 7.15 <0.01
CD8
+ T lymphocytes 0.23 ± 0.03 0.34 ± 0.04 0.02 0.17 ± 0.02 0.22 ± 0.03 <0.01
Tnaive 0.13 ± 0.02 0.11 ± 0.01 0.64 0.03 ± 0.01 0.03 ± 0.01 0.51
Tcm 0.04 ± 0.01 0.03 ± 0.01 0.59 0.04 ± 0.01 0.03 ± 0.01 0.64
Tem 0.07 ± 0.02 0.07 ± 0.02 0.73 0.06 ± 0.01 0.06 ± 0.01 0.76
Temra 0.02 ± 0.01 0.12 ± 0.02 <0.01 0.02 ± 0.01 0.11 ± 0.02 <0.01
Tmem 0.13 ± 0.03 0.22 ± 0.04 0.03 0.12 ± 0.02 0.19 ± 0.03 0.02
*CD28null 26.73 ± 2.82 50.95 ± 5.55 <0.01 24.92 ± 3.51 50.45 ± 4.44 <0.01
*CD57
+ 26.71 ± 5.11 68.12 ± 6.7 <0.01 34.09 ± 4.83 55.22 ± 7.26 0.06
CD4/CD8 ratio 2.32 ± 0.27 1.62 ± 0.18 <0.01 4.37 ± 0.90 2.0 ± 0.20 <0.01
absolute values are 10
6/mL, Tmem is sum of Tcm+Tem or sum of Tcm+Tem+Temra for CD4 and CD8 T lymphocytes, respectively.
* are percentages of CD4+ and CD8+ Tmem lymphocytes, respectively.
P-values represent the comparison between CMV- and CMV+
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Page 8 of 10but actually show expansion of the T cell population
under influence of CMV latency. The relative large
CMV-related increase in total T cell numbers (> 30%)
indicate a bystander effect on other T cells [10] which is
in accordance with the discrepancy noted between e.g.
the percentage of CMV-specific CD4
+ T cells and the
higher percentage of CD4
+CD28null cells [17,28].
In addition to the pleiotropic effects of CMV-seroposi-
tivity on T cell subsets in relation with age, the effects in
ESRD patients are again different. ESRD patients have a
remarkable contracted population of naive CD4
+ and
CD8
+ T cells at all ages. The causes of this Tnaive
lymphopenia are not certain but may involve reduced
thymic output, lack of IL-7 and increased activation-
induced apoptosis in ESRD patients [7,8]. Most strik-
ingly, the association between CMV-seropositivity and
increased expansion of CD4
+ T cells at young age was
not observed in ESRD patients. In addition, independent
of CMV-seropositivity an age-related progressive decline
of an already contracted naive CD4
+ T cell at young age
was observed. However, CMV-seropositivity showed an
add-on effect on CD4
+ Tnaive lymphopenia and was
associated with the development of terminally differen-
tiated effector-memory T cells in both the CD4
+ and
CD8
+ compartment. Similar to healthy individuals, the
appearance of CD28null T cells and increased CD57
expression was highly associated with CMV seropositiv-
ity. In CMV-seropositive ESRD patients, the percentage
of CD57 positive cells was significantly higher and the
percentage of CD4
+CD28null T cells increased with age.
Overall, CMV-seropositivity aggravates the ESRD-related
changes of the T cell immune system.
A unifying hypothesis may be that frequent CMV
reactivation [29], [30,31] causes a lifetime activation of
the immune system with an initial increase of CD4
+ T
cells at young age but over the years exhaustion of repli-
cative capacity with progressive decrease of naive T cells
[32-34]. In ESRD a similar process occurs with continu-
ous T cell activation possibly by the pro-inflammatory
state of uremia and increased susceptibility for activa-
tion induced cell death. The net effect is severe Tnaive
cell depletion and increased numbers of terminally dif-
ferentiated CD4
+ and CD8
+ memory T cells which is
aggravated by CMV reactivation. CMV reactivation is
triggered by inflammatory stimuli creating the possibility
that the pro-inflammatory condition of ESRD patients
leads to more frequent subclinical CMV reactivation
and even CMV disease [14,35].
The negative association of an CMV associated
immune risk profile with survival in the very old is
known and is likely also of clinical importance, but at a
much earlier age, in ESRD patients. Understanding the
combined effects of age, CMV seropositivity and ESRD
on T cell immunity may help to identify patients at risk
for a decreased vaccination response [36,37], at risk for
cardiovascular events [17], and may guide patient-tai-
lored immune suppression after kidney transplantation
[38].
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